John Wiley & Sons Inc is a global leader in research and learning providing content services platforms and knowledge networks to researchers students instructors professionals institutions and corporations The company operates as a predominantly digital enterprise with 83 percent of its adjusted revenue for fiscal year 2025 generated by digital products and services Its core activities include publishing scientific technical medical and scholarly journals offering digital…
John Wiley & Sons Inc is a global leader in research and learning providing content services platforms and knowledge networks to researchers students instructors professionals institutions and corporations The company operates as a predominantly digital enterprise with 83 percent of its adjusted revenue for fiscal year 2025 generated by digital products and services Its core activities include publishing scientific technical medical and scholarly journals offering digital courseware and assessments and delivering content platforms and services that support research and professional development Wiley is incorporated in the state of New York and has been operating since its founding in 1807
The company generates revenue through the sale of publishing content digital platforms and related services across its operational segments Research revenue comes from journal subscriptions transformational agreements open access publishing and licensing and ancillary products Learning revenue is derived from print and digital publishing digital courseware assessments and licensing and ancillary products The Held for Sale or Sold segment includes non-core businesses that were either held for sale or divested during the fiscal year Revenue is generated globally through direct sales to institutions consortia and professionals as well as through independent agents retailers and digital platforms
The company operates through the following segments: Research Learning and Held for Sale or Sold
• Research supports researchers professionals and learners in the discovery and use of research knowledge It provides over 1800 scientific technical medical and scholarly journals along with related content and services in physical sciences and engineering health sciences social sciences and humanities and life sciences Research customers include academic corporate government and public libraries funders of research researchers scientists clinicians engineers technologists scholarly and professional societies and students and professors Research products are sold globally through direct agreements with research libraries and library consortia independent subscription agents and direct sales to researchers and professional society members For fiscal year 2025 approximately 96 percent of Research revenue is generated by digital and online products and services Research publishing centers are located in Australia China Germany India the UK and the US.
• Learning includes Academic and Professional and offers scientific professional and education print and digital books digital courseware and assessment services for businesses and professionals Primary categories served include business and leadership technology behavioral health engineering architecture science and professional education Products are sold through brick-and-mortar and online retailers wholesalers college bookstores individual practitioners corporations distributor networks and government agencies Publishing centers are located in Australia Germany India the UK and the US For fiscal year 2025 approximately 60 percent of Learning revenue is from digital and online products and services.
• Held for Sale or Sold primarily consists of non-core businesses that were classified as held for sale until the date of sale as well as other businesses that were sold This includes University Services sold on January 1 2024 Wiley Edge sold on May 31 2024 except its India operations which were sold on August 31 2024 CrossKnowledge sold on August 31 2024 and other businesses sold in fiscal years 2024 and 2023 CrossKnowledge previously offered online learning and training solutions for global corporations and small and medium-sized enterprises Wiley Edge sourced students and professionals for technology and banking services careers and placed them with financial institutions technology companies and government agencies.
Wiley is one of the world’s largest publishers and a global leader in research and learning It maintains a strong position in the academic publishing industry with a top three ranking in terms of citations received according to the 2024 release of the Journal Citation Reports The company’s competitive advantages include its long-standing publishing alliances with prestigious societies such as the American Cancer Society the American Heart Association and the American Geophysical Union its digital content platform Wiley Online Library and its focus on high-growth areas such as open access publishing and content licensing for artificial intelligence models
Wiley serves a diverse customer base including researchers students instructors professionals institutions and corporations Specific customer types include academic corporate government and public libraries funders of research scientists clinicians engineers technologists scholarly and professional societies college bookstores individual practitioners corporations and government agencies The company also works with professional societies that sponsor or own journals and receive royalties or financial consideration for their partnership
Sectors:Communication Services · TechnologySector rationaleThe company's core business is publishing scientific, technical, medical, and scholarly journals, as well as academic books, which falls under the Publishing industry within Communication Services. A secondary sector of Technology is justified because the company operates as a 'predominantly digital enterprise' providing digital courseware, assessments, and content platforms that support research and professional development.Industries:PublishingCommunication ServicesPrimaryJohn Wiley & Sons is a global leader in publishing scientific, technical, medical, and scholarly journals, as well as print and digital books. Its revenue is generated through journal subscriptions, open access publishing, and the sale of educational and professional books to institutions and individuals.Education TechnologyTechnologySecondaryThe company provides digital courseware and assessment services for students and instructors, specifically within its Learning segment. These products are sold to college bookstores, universities, and individual learners.Classified using BQ-MICSCIK: 0000107140
Investment Thesis
▲ Bull case
Wiley is strategically positioned to capitalize on the AI-driven acceleration of scientific research output, with management highlighting a threefold increase in paper volume from researchers using AI tools, which directly amplifies demand for its proprietary content, journal subscriptions, and transformational agreements. The company's migration of over 80% of journals to the Research Exchange platform has transformed its content into AI-ready data, forming the foundational layer for subscription knowledge feeds and AI model training—areas where Wiley has already secured 10 corporate customers and a new LLM training partner outside the U.S. This infrastructure enables Wiley to monetize its content advantage through recurring, high-margin data services rather than relying solely on transactional publishing, with AI recurring revenue expected to triple from under 10% of current AI revenue next year. The Advanced open access brand, led by Advanced Science’s 50% revenue growth, is projected to exceed $70 million in fiscal 2026 with double-digit growth, leveraging author-funded models where revenue scales with both article volume and pricing power—both of which are bolstered by AI-driven research productivity. Furthermore, Wiley’s partnership ecosystem, including multiyear deals with IQVIA for clinical outcome assessments (now used by top 20 pharma companies) and Open Evidence for embedded clinical decision support, represents early but scalable entry into high-value workflows beyond traditional publishing, with the equity stake in Open Evidence signaling long-term commitment to owning a share of the value created when trusted scientific content informs real-time medical decisions. These initiatives are not incremental but structural, positioning Wiley to benefit from AI as an accelerator of core research demand rather than a disruptor, while its capital-light model—leveraging external partners like Virtusa for technology modernization—reduces capex burden and accelerates margin expansion, with adjusted EBITDA margin guidance raised to the high end of 25.5%-26.5% and operating cash flow nearly doubling year-over-year to $103 million, tracking toward a $200 million annual free cash flow target that supports sustained shareholder returns via a 4.5% dividend yield and a projected 3 million share repurchase for the year.
Wiley is strategically positioned to capitalize on the AI-driven acceleration of scientific research output, with management highlighting a threefold increase in paper volume from researchers using AI tools, which directly amplifies demand for its proprietary content, journal subscriptions, and transformational agreements. The company's migration of over 80% of journals to the Research Exchange platform has transformed its content into AI-ready data, forming the foundational layer for subscription knowledge feeds and AI model training—areas where Wiley has already secured 10 corporate customers and a new LLM training partner outside the U.S. This infrastructure enables Wiley to monetize its content advantage through recurring, high-margin data services rather than relying solely on transactional publishing, with AI recurring revenue expected to triple from under 10% of current AI revenue next year. The Advanced open access brand, led by Advanced Science’s 50% revenue growth, is projected to exceed $70 million in fiscal 2026 with double-digit growth, leveraging author-funded models where revenue scales with both article volume and pricing power—both of which are bolstered by AI-driven research productivity. Furthermore, Wiley’s partnership ecosystem, including multiyear deals with IQVIA for clinical outcome assessments (now used by top 20 pharma companies) and Open Evidence for embedded clinical decision support, represents early but scalable entry into high-value workflows beyond traditional publishing, with the equity stake in Open Evidence signaling long-term commitment to owning a share of the value created when trusted scientific content informs real-time medical decisions. These initiatives are not incremental but structural, positioning Wiley to benefit from AI as an accelerator of core research demand rather than a disruptor, while its capital-light model—leveraging external partners like Virtusa for technology modernization—reduces capex burden and accelerates margin expansion, with adjusted EBITDA margin guidance raised to the high end of 25.5%-26.5% and operating cash flow nearly doubling year-over-year to $103 million, tracking toward a $200 million annual free cash flow target that supports sustained shareholder returns via a 4.5% dividend yield and a projected 3 million share repurchase for the year.
Despite Wiley’s optimistic AI narrative, the company remains heavily dependent on traditional research publishing, which grew only 4% excluding AI revenue in Q3, and faces persistent headwinds in its Learning segment, where revenue declined 2% in the quarter and 7% year-to-date, with Professional down 5% and Academic growth of only 1% failing to offset weaknesses, suggesting that cost discipline and portfolio optimization may be masking underlying demand fragility in education markets. While management cites macro and channel headwinds—including Amazon inventory adjustments—as temporary, the sustained decline in Learning EBITDA margin (down 50 basis points year-to-date to 34.8%) and the 8% year-to-date drop in adjusted EBITDA for the segment indicate structural challenges beyond cyclicality, particularly as the company shifts focus toward higher-margin franchises without clear evidence of successful monetization in adjacent areas like automation or veterinary science partnerships. Furthermore, although Wiley highlights growth in India submissions (+43% YTD) and China (+43% YTD), these gains are concentrated in author-funded open access and submission volumes, not necessarily translating to proportional revenue growth, as open access revenue grows consistently above 20% but remains a smaller portion of the overall research publishing mix, and the company’s reliance on recurring revenue models (70% of research publishing) may be overstated given that AI-related recurring revenue remains under 10% of AI income, with management’s expectation of tripling this proportion next year contingent on unproven scalability of subscription knowledge feeds and clinical workflow integrations beyond early pilots with IQVIA and Open Evidence. The Virtusa partnership, while framed as a margin driver, involves a $150 million five-year managed services agreement that risks creating execution complexity, integration delays, or hidden costs associated with outsourcing core technology operations to a third party, particularly as Wiley transitions 80% of journals to the Research Exchange platform—a process that could disrupt workflows if not seamlessly coordinated with Virtusa’s implementation. Finally, Wiley’s confidence in U.S. federal research funding resilience may be premature, as the company acknowledges navigating “unfavorable comparables” and “soft market conditions” in learning, and while Congress enacted smaller reductions than proposed, the long-term trajectory of public research investment remains uncertain amid political volatility, potentially undermining the stability of its core subscription business that management claims is “must-have” across cycles—a claim not yet validated by persistent weakness in Learning and only modest ex-AI growth in Research Publishing.
Despite Wiley’s optimistic AI narrative, the company remains heavily dependent on traditional research publishing, which grew only 4% excluding AI revenue in Q3, and faces persistent headwinds in its Learning segment, where revenue declined 2% in the quarter and 7% year-to-date, with Professional down 5% and Academic growth of only 1% failing to offset weaknesses, suggesting that cost discipline and portfolio optimization may be masking underlying demand fragility in education markets. While management cites macro and channel headwinds—including Amazon inventory adjustments—as temporary, the sustained decline in Learning EBITDA margin (down 50 basis points year-to-date to 34.8%) and the 8% year-to-date drop in adjusted EBITDA for the segment indicate structural challenges beyond cyclicality, particularly as the company shifts focus toward higher-margin franchises without clear evidence of successful monetization in adjacent areas like automation or veterinary science partnerships. Furthermore, although Wiley highlights growth in India submissions (+43% YTD) and China (+43% YTD), these gains are concentrated in author-funded open access and submission volumes, not necessarily translating to proportional revenue growth, as open access revenue grows consistently above 20% but remains a smaller portion of the overall research publishing mix, and the company’s reliance on recurring revenue models (70% of research publishing) may be overstated given that AI-related recurring revenue remains under 10% of AI income, with management’s expectation of tripling this proportion next year contingent on unproven scalability of subscription knowledge feeds and clinical workflow integrations beyond early pilots with IQVIA and Open Evidence. The Virtusa partnership, while framed as a margin driver, involves a $150 million five-year managed services agreement that risks creating execution complexity, integration delays, or hidden costs associated with outsourcing core technology operations to a third party, particularly as Wiley transitions 80% of journals to the Research Exchange platform—a process that could disrupt workflows if not seamlessly coordinated with Virtusa’s implementation. Finally, Wiley’s confidence in U.S. federal research funding resilience may be premature, as the company acknowledges navigating “unfavorable comparables” and “soft market conditions” in learning, and while Congress enacted smaller reductions than proposed, the long-term trajectory of public research investment remains uncertain amid political volatility, potentially undermining the stability of its core subscription business that management claims is “must-have” across cycles—a claim not yet validated by persistent weakness in Learning and only modest ex-AI growth in Research Publishing.